Form 4: Syros Pharmaceuticals CFO Jason Haas Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Jason Haas, CFO of Syros Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units related to vesting.

Summary

  • Jason Haas, the Chief Financial Officer of Syros Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
  • On March 31, 2024, Haas acquired 2,000 shares of common stock upon the vesting of restricted stock units.
  • Also on March 31, 2024, Haas acquired 13,333 shares of common stock upon the vesting of restricted stock units.
  • On April 1, 2024, 4,732 shares were disposed of to cover tax withholding at a price of $5.12 per share.
  • Following these transactions, Haas directly owns 24,552 shares of common stock and holds 26,667 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation and does not inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CFO's transactions related to vested stock awards.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the change in the CFO's holdings.

Key Dates

DateDescription
02/15/2022Date of restricted stock unit award that vests in four equal annual installments commencing on March 31, 2023.
02/16/2023Date of restricted stock unit award that vests in three equal annual installments commencing on March 31, 2024.
03/31/2023Commencement date for vesting of restricted stock units granted on February 15, 2022.
03/31/2024Date of common stock acquisition upon vesting of restricted stock units.
04/01/2024Date of common stock disposal for tax withholding.
04/02/2024Date of Form 4 filing.

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Syros Pharmaceuticals, Jason Haas, CFO

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.